The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.

Publication Title

British journal of haematology

Document Type

Article

Publication Date

3-16-2020

Keywords

follicular lymphoma; ibrutinib; rituximab

Abstract

This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton's tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once-daily ibrutinib 560 mg continuously plus once-weekly rituximab 375 mg/m

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Hematology

Link to Full Text

Providence Full Text

Share

COinS